On the evening of August 18, Jincheng Pharm released its 2023 interim report, announcing that the company's operating income reached 1.705 billion yuan, a year-on-year decrease of 7.91%; the net profit attributable to shareholders of the listed company was 102 million yuan. In the announcement, it stated that the progress of key projects such as e-cigarette nicotine has been smooth, and they are expected to become important sources of income and profit in the future.
In terms of "key projects," Jincheng Pharmaceuticals mentioned that its subsidiary, Jincheng Pharmaceuticals, has made positive progress in several high-value-added key projects, which are expected to provide support for the company's medium to long-term performance. Among them, the e-cigarette nicotine project, which has attracted much attention, has achieved good production and sales, with sales reaching nearly 17 tons in the first half of the year.
In July of this year, Jincheng Pharm obtained a newly issued "Tobacco Monopoly Production Enterprise License," which allows the company to expand the production scale of e-cigarette nicotine, obtain new export qualifications, and extend the validity period of the certificate. This is beneficial for the company to legally carry out the production, sales, and export of e-cigarette nicotine. The company stated that it will continue to promote nicotine technology transformation and equipment upgrades, further improve product capacity, and continuously meet the downstream customers' demands.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
